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INTRODUCTION 
Heart disease was thought to be associated with diabetes as 
early as 1883, when Vergeley recommended testing the urine of 
patients with angina for glucose1. However, as more patients with 
diabetes survived following the discovery of insulin and 
improvements in the treatment of renal failure and infection, there 
was a marked increase in morbidity and mortality from 
cardiovascular disease. 
Diabetes mellitus is a strong risk factor for cardiovascular 
disorders, including coronary heart disease2,3. In previous studies, 
diabetes mellitus has been diagnosed in 10 to 24% of patients with 
acute myocardial infarction4,5,6. Furthermore, the age-adjusted 
prevalence of diabetes among patients with acute myocardial 
infarction has increased significantly over the past two decades. A 
true increase in diabetes, improved documentation in medical 
records and longer survival of diabetic patients are all factors 
underlying this increase 7. 
Patients with diabetes and myocardial infarction were older3 
,8, 9 ,10, 11 ,12,13 and more likely to be females14. They present more 
with anterior wall myocardial infarction, to receive thrombolysis 
later and to have triple-vessel coronary artery disease14. They have 
more severe coronary artery disease11 and poor left ventricular 
ejection fraction11, 12. Diabetes mellitus is an independent predictor 
for mortality after myocardial infarction3,10,11,15 and a two to 
fourfold increase in mortality due to coronary artery disease was 
noted among diabetics16. American Heart association AHA has 
recently stated that “diabetes is a cardiovascular disease”17. 
  Most studies3,6,10,17 concur that atrioventricular block is more 
frequent among diabetic than nondiabetic patients, the occurrence 
of ventricular tachycardia or fibrillation has been less consistent. 
Some reports16, 18 suggest that this arrhythmia is more common 
among patients with diabetes. However, in a recent observational 
study19, ventricular fibrillation occurred substantially less 
frequently among diabetic patients treated with glibenclamide 
compared with diet or other oral hypoglycemic agents. 
AIMS AND OBJECTIVES 
 
1. To study the influence of diabetes on the age of occurrence of 
STEMI. 
2. To study the gender distribution among Diabetic and 
Nondiabetic patients with STEMI. 
3. To study the incidence of painless STEMI in Diabetic and 
Nondiabetic patients. 
4. To study the influence of diabetes on the principal region of 
myocardial involvement in STEMI. 
5. To study the influence of diabetes on complications of STEMI. 
6. To evaluate the influence of diabetes on in-hospital mortality 
in STEMI patients. 
 
 
REVIEW OF LITERATURE 
ST-ELEVATION MYOCARDIAL INFARCTION 
DEFINITION 
 Epidemiological reports from the World Health Organization 
and American Heart Association beginning in the late 1950s 
required the presence of at least two of the following : characteristic 
symptoms, electrocardiographic changes, and a typical rise and fall 
in biochemical markers for the diagnosis of myocardial infarction20. 
This epidemiological approach was then generally adopted in 
routine clinical practice, although the rigor with which clinicians 
apply the electrocardiographic and biochemical criteria for 
infarction varies considerably. 
 Advances in the techniques for diagnosing MI, especially the 
introduction of assays for cardiac-specific troponins, were the 
impetus for a consensus document published jointly by the 
European Society of Cardiology and the American College of 
Cardiology21.  
 
 
 
 
Revised Definition of Myocardial Infarction MI 
Criteria for acute, evolving, or recent MI 
Either one of the following criteria satisfies the diagnosis for an 
acute, evolving, or recent MI : 
1. Typical rise and gradual fall troponin or more rapid rise and 
fall CK-MB of biochemical markers of myocardial necrosis 
with at least one of the following : 
 a. Ischemic symptoms  
b. Development of pathologic Q waves on the ECG 
reading 
c. ECG changes indicative of ischemia ST-segment 
elevation or depression 
d. Coronary artery intervention e.g., coronary 
angioplasty 
2. Pathological findings of an acute MI 
Criteria for established MI 
Either of the following criteria satisfies the diagnosis for 
established MI : 
1. Development of new pathological Q waves on serial ECG 
readings. The patient may or may not remember previous 
symptoms. Biochemical markers of myocardial necrosis may 
have normalized, depending on the length of time that has 
passed since the infarct developed.  
2. Pathological findings of a healed or healing MI 
 The revised definition of MI has important implications not 
only for clinical care of patients but also for tracking 
epidemiological trends, public policy, and clinical trials 22,23.  
 Coronary thrombus in the Anterior descending coronary artery 
Composition of Plaques 
 The atherosclerotic Plaque is composed primarily of fibrous 
tissue of varying density and cellularity with superimposed 
thrombus. Calcium, lipid-laden foam cells, and extracellular lipid 
each constitutes 5 to 10 percent of the remaining area. The 
atherosclerotic plaques that are associated with thrombosis and a 
total occlusion, located in infarct-related vessels, are generally 
more complex and irregular than those in vessels not associated 
with STEMI. Histological studies of these lesions often reveal 
plaque rupture or erosion. Coronary arterial thrombi responsible 
for STEMI are approximately 1 cm in length in most cases, adhere 
to the luminal surface of an artery, and are composed of platelets, 
fibrin, erythrocytes, and leukocytes. The composition of the 
thrombus may vary at different levels: a white thrombus is 
composed of platelets, fibrin, or both, and a red thrombus is 
composed of erythrocytes, fibrin, platelets, and leukocytes24. Early 
thrombi are usually small and non-occlusive and are composed 
predominantly of platelets.  
Plaque fissuring and disruption 
 In atherosclerotic plaques prone to disruption, there is an 
increased rate of formation of metalloproteinase enzymes such as 
collegenase, gelatinase, and stromelysin that degrade components 
of the protective interstitial matrix25. These proteinases can be 
elaborated by activated macrophages and mast cells that have been 
shown to accumulate in high concentration at the site of 
atheromatous erosion and plaque disruption in patients who died of 
STEMI25. Examination of specimens from atherectomy reveals a 
much higher content of macrophages and tissue factor in patients 
with unstable angina or STEMI compared with patients with 
chronic stable angina26. In addition to these structural aspects of 
vulnerable or high-risk plaques, stresses induced by intraluminal 
pressure, coronary vasomotor tone, tachycardia cyclic stretching 
and compression, and disruption of nutrient vessels combine to 
produce plaque disruption at the margin of the fibrous cap near an 
adjacent plaque –free segment of the coronary artery wall shoulder 
region of plaque27. A number of key physiological parameters such 
as systolic blood pressure, heart rate, blood viscosity, endogenous 
tissue plasminogen activator t-PA activity, plasminogen activator 
inhibitor-1 PAI-1 levels, plasma cortisol levels, and plasma 
epinephrine levels that exhibit circadian and seasonal variations 
are increased at times of stress. They act in concert to produce a 
heightened propensity to plaque disruption and coronary 
thrombosis, yielding the clustering of STEMI in the early morning 
hours, and especially in the winter and after natural disasters28.  
DIABETES AND CARDIOVASCULAR MORTALITY 
 Rancho Bernardo Study29, which followed subjects aged 40 to 
79 for 14 years found that death rates were increased in subjects 
with diabetes, the risk factor-adjusted relative odds were 3.3 in 
women and 1.9 in men. Factors associated with an increase in 
mortality rates among those with diabetes include male gender, 
black race, longer duration of diabetes, and insulin use30. Coronary 
artery and cerebrovascular disease, accounts for 65% of all deaths 
among persons with diabetes. Patients with type 2 diabetes and 
patients with type 1 diabetes have similar causes of death, 
including CAD and renal failure 31 32.  
Life expectancy is shortened, with diabetic males living, on 
average, 9.1 years less and diabetic females living 6.7 years less 
than their nondiabetic counterparts33. Haffner and colleagues 
examined the mortality among 1,000 persons with type 2 diabetes 
and 1,300 subjects without diabetes and found that the mortality of 
those with diabetes was similar to that for those without diabetes 
who had a myocardial infarction MI34. These data suggest that 
caregivers should treat individuals with type 2 diabetes as if they 
had experienced an MI. Mukamal et al.35. Studied 1,935 patients 
hospitalized with an acute MI and found that the mortality among 
those with diabetes in the short-term period was similar to that of 
the patients without diabetes who had an MI previously and twice 
that of patients without diabetes who had suffered their first acute 
coronary event. Malmberg et al.36 evaluated the findings of the 
OASIS Organization to Assess Strategies for Ischemic Syndromes 
registry and found that patients with diabetes hospitalized for 
unstable angina or non-Q-wave MI had the same long-term 
morbidity and mortality as patients without diabetes with 
established cardiovascular disease.  
 Over the past three decades, there have been significant 
decreases in cardiovascular mortality in the United States. 
However, the effect on mortality in patients with diabetes has 
lagged well behind that in the general population37. The death rate 
among nondiabetic men with CAD decreased by 36.4% as compared 
to a decrease of 13.1% for diabetic men, and the death rate among 
nondiabetic women decreased by 27% as compared to an increase of 
23% among diabetic women 37. 
PREVALENCE AND RISK FACTORS FOR CORONARY 
ARTERY DISEASE IN TYPE 1 DIABETES 
 Long-term follow-up of patients with type 1 diabetes has 
demonstrated that the first cases of clinically manifest CAD occur 
late in the third decade or in the fourth decade of life regardless of 
whether diabetes developed early in childhood or during late 
adolescence. CAD risk increases rapidly after the age of 40, and by 
the age of 55 years, 35% of men and women with type 1 diabetes die 
of CAD32 compared with 8% of those without diabetes. Women with 
type 1 diabetes lose most of the inherent protection from CAD 
observed in women without diabetes32,38,39. The occurrence of severe 
coronary artherosclerosis before the age of 55 in a subset of 
patients with type 1 diabetes regardless of whether diabetes 
developed in childhood or adolescence suggests that diabetes 
mainly accelerates the progression of early atherosclerotic lesions 
that commonly occur, even in the absence of diabetes, at a young 
age in the general population 32.  
 
 Patients with type 1 diabetes followed from the onset of 
microalbuminuria developed CAD eight times more frequently than 
patients without microalbuminuria40. Krolewski et al 31 reported 
that the risk of development of CAD in patients with persistent 
proteinuria was 15 times higher than the risk among those without 
proteinuria. Microalbuminuria in type 1 diabetes is therefore not 
only a marker for renal disuse but also a potent marker of CAD 
risk. 
Prevalence and Risk Factors for Coronary Artery Disease in 
Type 2 Diabetes 
 Type 2 diabetes increases relative risk of cardiovascular 
disease two to fourfold compared with the risk in the general 
population41,42,43,44. The increase in cardiovascular risk is 
particularly high in women. The protection against atherosclerosis 
in premenopausal women is almost completely lost in women with 
diabetes45,46. 
 Traditional risk factors play an important role in the 
development of atherosclerosis in subjects with diabetes, the rate of 
cardiovascular mortality and morbidity in persons with diabetes 
exceeds by 50% the rate predicted by these risk factors.  
 Many of these patients with type 2 diabetes have several risk 
factors for CAD. The term metabolic syndrome was first used by 
Gerald Reaven in 198847 to describe this clustering of risk factors 
including hypertension, dyslipidemia, hyperglycemia, and insulin 
resistance. The National Cholesterol Education Program Adult 
Treatment Panel III (ATPIII) guidelines for cholesterol 
management in 2001 recognized that the metabolic syndrome is a 
collection of the risk factors mentioned above, as well as abdominal 
obesity 48.  
PATHOPHYSIOLOGY OF DIABETIC CARDIOVASCULAR 
COMPLICATIONS 
Insulin levels, Insulin resistance and Hyperglycemia  
 Insulin resistance that is present many years or more before 
the clinical onset of overt diabetes is associated with other 
atherogenic risk factors, such as hypertension, lipid abnormalities, 
and a procoagulant state49,50,51,52,53,54,55. Several studies have shown 
an inverse correlation between insulin sensitivity and 
atherosclerosis56,57,58. The Bruneck Study database suggest59 that 
these risk factors are present in 84% of patients with type 2 
diabetes. Thus, an increased prevalence of CAD is apparent in 
patients with impaired glucose tolerance42,44,60 and in those with 
newly diagnosed type 2 diabetes61,62. The duration of insulin 
resistance among hyperglycemic and diabetic individuals probably 
contributes to the development of atherosclerosis. However no 
obvious association between the extent or severity of macrovascular 
complications and the duration or severity of type 2 diabetes38, 63 
has been found, most likely because the duration of insulin 
resistant is often unknown.  
 Another possibility is that the serum insulin level and not 
insulin resistance has direct cardiovascular effects. Despres and 
colleagues64 followed 2,000 diabetic men without clinically overt 
CAD for 5 years and found that those who had a cardiovascular 
event had serum insulin levels that were 18% higher than those in 
controls.  
 Serum glucose levels may be an important risk factor for 
cardiovascular disease. Andersson and Svardsudd65 demonstrated 
that fasting serum glucose levels are independently related to all-
cause and cardiovascular mortality. The San Antonio Heart Study66 
showed similar findings for subjects in the highest quartile of 
fasting glucose levels, who had a 4.7 times greater risk of 
cardiovascular disease than did those in the first two quartile levels 
combined.  
 The direct relationship between glucose levels and 
cardiovascular disease also is seen in patients with type 1 diabetes. 
A 1% increase in levels of glycosylated hemoglobin doubled the 
increase in cardiovascular disease 67. Several studies have shown a 
direct relationship with the serum glucose levels on clinical events, 
including MI and strokes, with glucose levels ranging from an 
abnormal glucose tolerance test to frank diabetes68,69,70. This graded 
effect of serum glucose levels on clinical events may be due in part 
to a direct effect on the vasculature, as evidenced by a similar 
direct relationship of serum glucose levels to the intima-media 
thickness of the carotid (as a marker for the presence and degree of 
atherosclerosis). The Atherosclerosis Risk in Communities (ARIC) 
study demonstrated that fasting glucose tolerance was directly 
related to carotid wall thickness in individuals free of symptomatic 
cardiovascular disease71.  
 The level of chronic hyperglycemia, as determined by 
measurements of glycosylated hemoglobin, may also be an 
independent risk factor for coronary heart disease, particularly in 
women72,73. Recent prospective studies demonstrated that 
microalbuminuria in patients with type 2 diabetes is also an 
independent predictor of increased cardiovascular mortablity74, 75. 
Insulin resistance may play an important role as a risk factor in the 
development of diabetic cardiovascular disease. Hyper-insulinemia 
may be the mechanism by which the effect of hyperglycemia results 
in atherosclerosis. Insulin level is elevated patients with the 
metabolic syndrome. The possibility that insulin resistance could 
result in an increase in cardiovascular disease was first 
demonstrated in population studies that showed an association 
between fasting insulin levels and cardiovascular mortality 
56,76,77,78. The relationship of insulin levels and cardiovascular 
disease is further strengthened by basic research studies that 
showed the effect of insulin on various possible mediators for the 
development of atherosclerosis, specifically the increase in PAI-I 
and the mitogenic effect on smooth muscle cells in vitro79. 
 
Dyslipidemia 
 An important mechanism for the development of diabetic 
atherosclerosis is dyslipidemia. The central feature of diabetic 
dyslipidemia is increased levels of VLDL due both to increased 
production of VLDL and to decreased catabolism of triglyceride-rich 
lipoproteins, including chylomicrons. The increase in hepatic 
production of VLDL occurs in response to increased delivery of fatty 
acids from (a) decreased free fatty acid uptake from the striated 
muscle and (b) increased delivery of the free fatty acids from the 
increased adipose tissue associated with central obesity. 
 The increase in triglyceride-rich lipoproteins accumulates not 
only because of increased VLDL production but also because of 
decreased catabolism of triglyceride lipoproteins. Lipoprotein 
lipase, which plays an important role in the metabolism of 
triglyceride-rich lipoproteins and in particular chylomicrons, is 
decreased in uncontrolled type 2 diabetes.  
 The increased level of triglyceride-rich lipoproteins provides 
an increase in substrate for the cholesterol ester transfer protein. 
This promotes the flux of cholesterol from HDL particles, which 
results in decreased HDL levels, a common finding in type 2 
diabetes.  
 One mechanism of the protective effect of HDL against 
atherosclerosis may be its ability to prevent oxidation of LDL. 
There may be qualitative differences in HDL from patients with 
poorly controlled diabetes that may make it a less effective 
antioxidant than HDL from normal individuals80.  
 The dyslipidemia of diabetes is not characterized by marked 
elevations of LDL, there are differences in the LDL type found in 
patients with type 2 diabetes. Specifically, the LDL is smaller and 
denser than typical LDL particles81, have a greater tendency to 
undergo oxidation, which accelerates the atherosclerotic process.  
Increased Oxidative Stress in Diabetes 
 There is recent evidence that increased oxidative stress in 
diabetes contributes to the development of diabetic complications. 
This increased stress may be due in part to the decreased 
availability of antioxidants such as ascorbic acid, vitamin E, uric 
acid, and glutathione. In addition, there may be an increase in lipid 
peroxidation products and superoxide anion products, which may 
be lead to altered vascular function 82,83,84.  
 Increase in oxidative stress may be the result of several 
pathways, including advanced glycation end product (AGE) 
production; small, dense LDL formation; altered polyol activity; or 
imbalance in the redox state 85. The activation of this polyol 
pathway is due to the conversion of glucose to sorbitol via aldolase 
reductase, which has been associated with microvascular 
complications 86,87.  
 
Advanced Glycation End Products in Diabetes 
 AGEs occur as a result of the nonenzymatic glycation of both 
lipids and proteins. Initially, a labile covalent bond develops 
between the aldehyde of the glucose molecule and the amino acid 
side chain on both sugars and lipids. Specifically, glucose is 
covalently bound mainly to lysine residues in proteins, forming 
fructose-lysine residues. This reaction results in the development of 
a Schiff base, which, in turn, undergoes another chemical reaction 
to form a ketoamine, termed an Amadori product. These products 
result in cumulative oxidative damage to proteins. These products 
include CML88 and pentosidine89. The increased levels of 
pentosidine and CML correlate with the severity of diabetic 
complications, including nephropathy, retinopathy, and vascular 
disease. One such Amadori product is glycated (or glycosylated) 
hemoglobin A1c (HbA1c), which is commonly used to monitor 
glycemic control in diabetic patients. Since both free-radical 
oxidation and glycation are involved, these substances are also 
called glyoxidation products.  
 AGEs cross-link to the proteins composing the extracellular 
matrix and vascular basement membrane, which results in reduced 
solubility and decreased enzymatic digestion 90,91. AGE formation 
also prevents proper assembly of basement proteins, thereby 
altering their function. This in turn may alter the ability of cells to 
bind to their substrates.  
 Enhanced glycation, oxidation, and glyoxidation of lipo-
proteins have been postulated as a possible cause for the 
development of diabetic macrovascular disease. Certainly there are 
increased levels of AGE-modified LDL-apoprotein and LDL-lipid in 
persons with diabetes relative to levels in persons without diabetes 
92. This would suggest that even in the face of similar glycemic 
control and other cardiovascular risk factors, the development of 
diabetic vascular complications would depend on differences of 
oxidative stress as well as on the tissue level of antioxidants.  
Thrombosis and Fibrinolysis in Diabetes 
 Plaque disruption with overlying thrombosis is a major cause 
of acute coronary syndromes, including MI, sudden death. There 
are three underlying mechanisms for this prothrombosis: 
heightened platelet reactivity, increased procoagulant activity, and 
decreased antithrombotic and fibrinolytic activity.  
 The platelets of diabetic individuals appear to have an 
increased adherence to the vessel wall and increased circulating 
platelet mass93. Platelet aggregometry studies that measure in 
vitro platelet reactivity have demonstrated increased aggregation 
of platelets in response to the agonists ADP, collagen, and thrombin 
and even spontaneous aggregation of platelets without any 
agonist94,95,96,97,98. Assessment of platelet reactivity in vivo by 
measurement of blood or urine metabolites released from activated 
platelets such as thromboxane B2 has shown increased reactivity 
relative to that of normal healthy controls 94,95.  
 Patients with diabetes have increased concentrations of 
fibrinogen, von Willebrand factor, and factor VII 99,100,101. The level 
of serum fibrinogen correlates with the levels of proinsulin and 
insulin in the blood 102. 
 Several reports indicate that the activity of antithrombotic 
factors, including protein C and antithrombins, are decreased in 
subjects with diabetes, which further potentiates the 
hypercoagulable state 103,104,105,106.  
 Fibrinolysis is also impaired in individuals with diabetes, 
particularly those with type 2 diabetes 107,108. This impairment may 
be due to the increased activity of PAI-1 in the blood, which 
counteracts the action of native tissue plasminogen activator (t-PA) 
to induce fibrinolysis. PAI-1 is elevated not only in resting states 
but also in response to physiologic stimuli. The serum level of PAI-1 
may be elevated as a result of several factors, including elevated 
serum levels of insulin, lipids, and glucose109.  
Endothelial Function and Diabetes 
 Alterations in endothelial function may play an important 
role in the development of diabetic complications. 
 The vascular endothelium has been shown to be important in 
modulating blood cell-vessel wall interaction, regulating blood flow, 
angiogenesis, lipoprotein metabolism, and vasomotion. An 
important mediator in maintaining vascular homeostasis is 
endothelium-derived relaxing factor (EDRF)110 which has since 
been found to be nitric oxide111. The release of nitric oxide activates 
soluble guanylate cyclase, resulting in the formation of cyclic 
guanosine monophosphate (cGMP), which, in turn, activates cGMP-
dependent protein kinases, resulting in relaxation of vascular 
smooth muscle112,113,114,115. Alterations in the expression, release, or 
activity of EDRF may play an important role in the initiation and 
progression of both micro-and macrovascular disease. Several 
studies have shown that endothelial-dependent vasodilator 
function is impaired in patients with type 1 diabetes without 
hypertension and dyslipidemia116. This impairment is in contrast to 
that in patients with type 2 diabetes, who have an impairment of 
both endothelial – dependent and endothelial-independent (smooth 
muscle) vasodilator function 117,118.  
 Acute hyperglycemia impairs endothelial-dependent 
vasodilatation in both macro-and microvessels119. Insulin also may 
play a role. Insulin results in vasodilatation due in part to nitric 
oxide production. Glucose-clamp experiments with insulin infusion 
have shown that subjects with type 2 diabetes have little 
improvement in endothelial-dependent vasodilatation relative to 
that in subjects without diabetes119. As stated previously, there 
appears to be an increase in oxygen-derived free radicals in the 
diabetic state. Several studies have shown that high doses of 
vitamin C can improve endothelial-dependent vasodilatation in 
patients with both type 1 and type 2 diabetes120,121. Intensive lipid 
lowering by Statin therapy does not improve vasoreactivity in 
patients with type 2 diabetes, suggesting that mechanisms other 
than dyslipidemia are responsible for endothelial dysfunction 122.  
Silent Ischemia 
 The propensity of patients with diabetes to present with 
either silent or unrecognized MI is well established123,124. Atypical 
symptoms such as confusion, dyspnoea, fatigue, or nausea and 
vomiting were the presenting complaint in 32% to 42% of patients 
with diabetes with MI compared with 6% to 15% of patients 
without diabetes123,125. Several groups have reported that the 
detection of silent ischemia by various noninvasive techniques, 
including treadmill exercise testing126,127, ambulatory holter 
monitoring128 and exercise thallium scintigraphy129,130,131,132, is 
more common in patients with diabetes than in those without 
diabetes. This finding, however, is not supported by all 
studies133,134.  
 A plausible explanation for painless infarction and ischemic 
episodes in patients with diabetes is autonomic neuropathy with 
involvement of the sensory supply to the heart. In autopsies of 
patients with diabetes who died of silent MIs, typical diabetic 
neuropathic changes were found in the intracardiac sympathetic 
and parasympathetic fibers135, and several studies correlated 
abnormalities in autonomic function in patients with silent 
ischemia126,128,130,136. The anginal perceptual threshold-the time 
from the onset of myocardial ischemia (assessed by ST segment 
depression) to the onset of chest pain during exercise testing -is 
prolonged in patients with diabetes compared with those without 
diabetes. This delay in the perception of pain may be related to the 
impairment of autonomic nervous function136.  
Acute Coronary Syndromes in Patients with Diabetes 
 Acute ischemic events represent a major cause of death in the 
diabetic population61. Diabetic patients who suffer an MI have a 
higher mortality than nondiabetic patients both in the acute phase 
and on long-term follow-up. Numerous studies have shown that in-
hospital mortality rates from MI in patients with diabetes are 1.5 
to 2-fold higher than in patients without diabetes137,138,139,140. 
Diabetes remains an independent predictor for a poor prognosis in 
the thrombolytic era. In the Thrombolysis and Angioplasty in 
Myocardial Infarction (TAMI) trials, the in-hospital mortality rate 
was nearly twice as high in patients with diabetes, with more 
congestive heart failure and twice the rate of clinically recognized 
reinfarction 137. In the Global Utilization of Streptokinase and 
Tissue Plasminogen Activator for Occluded Coronary Arteries 
(GUSTO-I) trial, mortality at 30 days was highest among patients 
with diabetes treated with insulin (12.5%) compared with patients 
with diabetes not treated with insulin (9.7%) and nondiabetic 
(6.2%) patients (p<0.001)141. Similar results have been reported 
from the other large studies142,143,144. Diabetes is also a risk factor 
for cardiogenic shock in the setting of acute ischemic syndromes145. 
Overall, despite the overall improvement in survival from an acute 
MI with thrombolysis, the in-hospital mortality rates in patients 
with diabetes remain 1.5 to 2 times higher than in patients without 
diabetes 141,144.  
 This increased in-hospital mortality among patients with 
diabetes with acute MI is due predominantly to an increase in the 
incidence of congestive heart failure 138,140,146,147 although increases 
in the incidence of reinfarction, infarct extension, and recurrent 
ischemia have also been reported 138,139,140,147,148. 
Studies using serial determinations of total creatine kinase 
activity146,147 radionuclide ventriculography149, or echocardiography 
have found no evidence that patients with diabetes sustain more 
extensive infarctions than their nondiabetic counterparts150. Thus, 
congestive heart failure and cardiogenic shock are more common 
and more severe in subjects with diabetes than would be expected 
from the size of the index infarction144,146,147,149,151,152. The 
observation that clinical manifestations of heart failure occur in 
patients with diabetes despite a modest decrease in left ventricular 
ejection fraction (EF) led to the suggestion that preexisting 
diastolic dysfunction is a major culprit in the congestive 
symptoms140. Indeed, subclinical diabetic cardiomyopathy, which is 
characterized by diastolic dysfunction153, is likely to be an 
important factor in this setting.  
It should be emphasized, however, the reductions in both left 
ventricular EF149,154 and the regional EF of the noninfarcted 
myocardium137,149,153 have been well documented in patients with 
diabetes following MI as compared with patients without diabetes. 
For example, early angiography in the TAMI trials has 
demonstrated worse ventricular function in the noninfarcted zone 
in patients with diabetes 137.  
The performance of the left ventricle following MI is 
determined largely by the extent of coronary disease155 and the 
quality of collateral circulation. Thus, the diffuse nature of 
coronary atherosclerosis in diabetes may contribute to systolic 
dysfunction of the noninfarcted myocardium. Moreover, a recent 
study has shown that patients with diabetes have a reduced ability 
to develop collateral blood vessels in the presence of CAD156, a 
finding that also may explain the more frequent occurrence of 
postinfarction angina and infarct extension139,140,148,150. 
Patients with diabetes surviving MI also suffer higher late 
mortality rates than patients without diabetes140,148,157,158,159. Late 
mortality is related primarily to both recurrent MI and the 
development of new congestive heart failure 144,150,158,159,160. 
CONGESTIVE HEART FAILURE AND DIABETES 
 CAD is the most common cause of congestive heart failure in 
the overall U.S.161, and diabetic 162 populations. Diffuse CAD can 
lead to nontransmural infarction with patchy necrosis and 
myocardial fibrosis, resulting in an impairment of systolic function. 
Myocardial ischemia may result not only in systolic dysfunction but 
also in diastolic dysfunction163,164. In the setting of an acute MI, 
patients with diabetes have been reported in some studies to 
develop heart failure up to 50% of the time165. The GUSTO-1 trial 
demonstrated that heart failure developed in 27% of the subjects 
with type 1 diabetes compared with 20% of those with type 2 
diabetes and 15% of those in the nondiabetic group. This amounts 
to the occurrence of heart failure almost twice as frequently in the 
diabetic population relative to the nondiabetic population140. 
Persons with diabetes are also almost twice as likely as those 
without diabetes to develop heart failure as a result of an acute 
coronary syndrome (7.2% vs. 3.8%). 
 The presence of heart failure in the diabetic population is 
associated with a poorer long-term prognosis. This GUSTO-1 study 
demonstrated that cardiac mortality at 30 days in the subjects with 
type 1 diabetes was 12.5% compared with 9.7% in those with type 2 
diabetes and 6.2% in those without diabetes. This poorer outcome 
was not the result of a larger MI but may have been due to 
response of the noninfarcted myocardium to the infarct. The MILIS 
database demonstrated that the prognosis of patients with diabetes 
was worse relative to that of patients without diabetes (4-year 
cardiac mortality rates of 25.9% in those with diabetes and 14.5% 
in those without diabetes), despite the presence of smaller infarcts 
[as measured by peak creatine phosphokinase (CPK) or area under 
the curve] and fewer Q-wave infarcts140. The GUSTO-1 study also 
found that vessel patency after MI did not explain this worse 
prognosis either, since there were similar degrees of infarct-related 
patency at 90 minutes in the patients with or without 
diabetes166.Compensatory hyperkinesis of noninfarcted walls, 
which is frequently found in subject without diabetes immediately 
after MI, is often blunted in the patient with diabetes166. This may 
account for the increased incidence of heart failure.  
 
  
 
 
 
 
 
 
 
 
 
 
Materials and 
Methods    
MATERIALS AND METHODS 
Setting 
 A randomised comparative study and analysis with patients 
drawn from Intensive coronary care unit. 
Study Population 
 The study was conducted over a 2 year period from June 2004 
to June 2006. Cases were drawn from Intensive coronary care unit, 
Department of Cardiology, Kilpauk Medical College. Informed 
consent was taken from all participants of the study. The clinical 
profiles of patients admitted with ST elevation MI (STEMI) were 
analyzed. The patients were grouped into diabetics and 
nondiabetics based on their previous history of diabetes. A total of 
2113 patients were initially chosen for the study. 671 were found to 
be diabetic and the remaining 1442 were nondiabetic. On 
application of exclusion criteria, 458 and 1036 patients were 
excluded from the diabetic and nondiabetic group respectively. 
Eight of the 113 diabetic patients and 14 among the 406 
nondiabetic patients expired as a result of cardiogenic shock soon 
after admission. 9 and 6 patients expired due to other complications 
of acute myocardial infarction in the diabetic and nondiabetics 
groups respectively. In the above patients blood sugar values and 
echo evaluation could not be performed.  
 
Inclusion Criteria 
 Patients with STEMI evidenced by ECG and clinical 
symptoms <24 hrs 
Patients with age above 20 years were chosen for the study.  
Exclusion Criteria 
• Patients with previous history of hypertension. 
• Patients with previous history of MI. 
Data Collection and Assessment 
Information collected consisted of basic data, including name, 
sex, age and occupation. The nature of habitat, whether 
sedentary lifestyle or manual labourer, was recorded. Main 
presenting complaint at the time of admission was recorded 
from the patients. 
 Previous history of diabetes was sought including the 
duration and regularity of treatment. Patients meeting the 
exclusion criteria were excluded from the study by detailed history 
and clinical examination of all systems.  
Vitals were recorded. 
Cardiovascular examination of patients done and patients 
classified according to Killips classification. 
Random blood sugar and ECG was taken at the time of 
admission. The region of myocardial damage was identified with 
the help of ECG. 
Patient was then treated for the acute coronary event (viz. 
thrombolysed or anticoagulated) Fasting blood sugar was sent the 
following morning. 
All complications including mortality following the 
myocardial infarction during the stay in ICCU were noted. 
Echocardiography was performed at the time of discharge 
and ejection fraction calculated. 
Statistical Methods 
The data obtained from the study was analyzed for statistical 
significance using the Students t test, Chi square and Fischer’s 
Test. Values were expressed as mean and standard deviation. 
Calculation was done using SPSS software with the assistance of 
our college statistician and ICMR research worker 
Reference Criteria Used In This Study 
ST Elevation Myocardial Infarction 
The ECG criteria for the diagnosis of STEMI as outlined in 
the MILIS study are the presence of any one of the following in the 
setting of chest pain: (1) new or presumably new Q waves (at least 
30 ms wide and 0.20 mv deep) in atleast two leads from any of the 
following (a) leads II, III or AVF ;(b) leads V1 through V6 or  (c) 
leads I and AVL ;(2) new or presumably new ST-T segment 
elevation(>0.10 mv measured 0.02 s after the J point in two 
contiguous leads) or (3) a complete left bundle branch block in the 
appropriate clinical setting 167. 
Localization of Region of Myocardial Infarction in ECG 
• Extensive Anterior wall (AWMI) – Reflected by typical 
infarction pattern in standard lead I, AVL and all precordial 
leads 
• Anteroseptal wall (ASMI) – Reflected by infarction pattern in 
leads V1 – V4. 
• Anterolateral wall (ALMI) – Reflected by infarction pattern 
in leads I, AVL &V4 – V6. 
• Inferior wall (IWMI) – Reflected by infarction pattern in 
leads II,III & AVF168. 
 
 
Killip Classification 
Based on clinical examination169 
Class Definition 
I No signs of pulmonary or venous congestion 
II Moderate heart failure evidenced by rales at lung base, S3, 
Tachypnea or Signs of Rt. heart failure 
III Severe heart failure, Pulmonary edema 
IV Shock with systolic blood pressure <90mm Hg, Signs 
peripheral vasoconstriction, Peripheral cyanosis, Mental 
confusion. Oliguria 
Ventricular Tachycardia 
A series of 3 or more consecutive ventricular ectopic beats 
that are recorded in rapid succession170. 
Sustained Ventricular Tachycardia 
Ventricular tachycardia that persists for >30s or requires 
termination due to hemodynamic collapse171. 
Ventricular Fibrillation 
ECG showing completely irregular, chaotic and deformed 
deflections of varying height, width and shape170. 
Complete Heart Block 
Complete interruption of AV conduction evidenced by AV 
dissociation and slow ventricular rate172. 
Blood Glucose Estimation  
Method : In this study we used GOD/POD method for 
estimation of fasting and random blood sugar.  
Principle : Glucose is oxidized by the enzyme Glucose 
Oxidase (GOD) to give D-Gluconic acid and hydrogen peroxide. 
Hydrogen peroxide in presence of enzyme Peroxidase (POD) 
oxidizes phenol which combines with 4 aminoantipyrine to produce 
a red colored quinonimine dye. The intensity of the color developed 
is proportional to glucose concentration in the sample.  
GOD 
D- glucose +H2O+O2------------------> D – gluconic acid + H2O2 
H2O2 +4 Amonoantipyrine + Phenol -----------------> Red 
Quinonimine dye + H2 
Reagents  
1. Enzyme reagent  
2. Buffer solution  
3. Glucose standard 100 mg% 
Normal Values    
Fasting : 70– 100 mg / dl – Normal   
>100 – 125 mg/dl – Impaired fasting glucose  
≥ 126 mg/dl – Diabetes mellitus  
After 2 hours of injection of 75 gms glucose.  
<140 mg/dl- Impaired Glucose tolerance test 
   >200 mg/dl – diabetes mellitus173.
  
 
 
 
 
 
 
 
 
 
 
 
 
Observation and 
Analysis  
OBSERVATION AND ANALYSIS 
 
PATIENTS FROM CARDIOLOGY OP 
 
 Diabetic   : 113 
 Non-diabetic  : 406 
 
TABLE – 1 
 
DISTRIBUTION ACCORDING TO AGE 
 
Diabetic Non Diabetic 
Age 
No. Percentage  No. Percentage 
≤ 30 0 0 7 1.72 
31-40 16 14.16 58 14.30 
41-50 22 19.47 121 29.80 
51-60 36 31.86 115 28.32 
61-70 31 27.43 70 17.24 
> 70 8 7.08 35 8.62 
Total 113 100% 406 100% 
 
TABLE – 2 
 
MEAN AND STANDARD DEVIATION  
 
Group Number Mean S.D. Significance 
Diabetic 406 53.23645 ± 12.13701 
Non 
Diabetic 
113 55.0531 ± 10.98606 
P > 0.05 NS 
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 TABLE - 3 
DISTRIBUTION ACCORDING TO GENDER  
 
Diabetic Non Diabetic 
Sex 
No. Percentage  No. Percentage 
Female 33 29.20 66 16.25 
Male 80 70.80 340 83.75 
Total 113 100% 406 100% 
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TABLE - 4 
DISTRIBUTION ACCORDING TO OCCUPATION 
 
Diabetic Non Diabetic 
Occupation  
No. Percentage  No. Percentage 
Manual 
Labour 
65 57.52 295 72.60 
Sedentary  48 42.48 111 27.40 
Total 113 100% 406 100% 
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TABLE - 5 
DISTRIBUTION ACCORDING TO THE PRESENCE OR 
ABSENCE OF CHEST PAIN 
 
Chest Pain 
Group 
Present Absent 
Total 
Diabetic 90 23 113 
Non Diabetic  392 14 406 
 
χ2 =   38.08 
P value < 0.001 (Significant) 
Odds Ratio : 7.16 
 Non chest pain presentation was 7.16 times more common in 
diabetic compared to Non diabetics.  
 
 
 
TABLE - 6 
 
DISTRIBUTION ACCORDING TO THE DURATION OF 
DIABETICS  
 
Duration Number Percentage 
< 5 years 70 61.95 
5-10 41 36.28 
> 10 years 2 1.77 
Total 113 100% 
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TABLE - 7 
DISTRIBUTION ACCORDING TO REGULARITY OF 
DIABETIC  TREATMENT 
 
Treatment  Number Percentage 
Regular 58 51.32 
Irregular 55 48.68 
Total 113 100% 
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TABLE - 8 
 
MEAN AND STANDARD DEVIATION OF FASTING AND  
RANDOM BLOOD SUGARS IN DIABETIC PATIENTS 
 
Blood Sugar Mean SD 
Fasting  175.61 ± 54.05 
Random 252.50 ± 76.40 
 
 
 
 
 
TABLE - 9 
 
DISTRIBUTION ACCORDING TO KILLIP 
CLASSIFICATION 
 
Killip I II III IV Total 
Diabetic 66 36 3 8 406 
Non 
Diabetic  
371 19 2 14 113 
 
χ2 = 80.07 
P value  <0.001  significant  
 Diabetic patients showed higher Killip class when compared 
to  non diabetics.  
TABLE - 10 
 
DISTRIBUTION ACCORDING TO THE WALL INVOLVED IN 
MYOCARDIAL INFARCTION 
 
Wall Diabetic Non Diabetic  
AWMI 96 243 
Others 17 163 
Total 113 406 
 
χ2 = 24.54 
P value < 0.001 significant  
Odds ratio : 3.79 
 
 Diabetic patients had 3.79 times anterior wall myocardial 
infarction compared to non diabetic patients.  
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 TABLE - 11 
DISTRIBUTION ACCORDING TO EJECTION FRACTION 
 
Diabetic Non Diabetic Ejection 
Fraction  No. Percentage  No. Percentage 
≤ 40 9 8.82 2 0.51 
41-50 44 43.14 23 5.88 
≥ 51 49 48.04 366 93.61 
Total 102 100% 406 100% 
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TABLE - 12 
DISTRIBUTION ACCORDING TO THE PRESENCE OR 
ABSENCE OF CARDIAC FAILURE 
Congestive  Cardiac failure 
Group 
Present Absent 
Total 
Diabetic  44 69 113 
Non Diabetic 40 366 406 
 
χ2 = 55.02 
P value < 0.001 significant  
Odds ratio : 5.83 
Cardiac failure was 5.83 times more common in diabetics 
compared to non diabetics. 
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TABLE - 13 
DISTRIBUTION ACCORDING TO THE PRESENCE OR 
ABSENCE OF VENTRICULAR ARRYTHMIAS 
Ventricular arrhythmias  
Group 
Present Absent 
Total 
Diabetic  7 106 113 
Non Diabetic 6 400 406 
 
χ2 = 8.04 
P value =  0.0045 significant  
Odds ratio : 4.40 
 Ventricular arrhythmias were 4.4 times more common in 
diabetics compared to non diabetics.  
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TABLE - 14 
DISTRIBUTION ACCORDING TO THE PRESENCE OR 
ABSENCE OF COMPLETE HEART BLOCK 
Complete Heart Block  
Group 
Present Absent 
Total 
Diabetic  8 105 113 
Non Diabetic 2 404 406 
 
 An expected cell value is less than 5. 
Fishers exact 2 tailed test used. 
P = 0.00012 significant. 
 Complete Heart blocks were more common in diabetics when 
compared with non diabetics in myocardial infarction. 
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TABLE - 15 
DISTRIBUTION ACCORDING TO MORTALITY 
 
Group  Dead Alive  Total 
Diabetic  17 96 113 
Non Diabetic 20 38.6 406 
 
χ2 = 13.67 
P value < 0.001 significant  
Odds ratio : 3.42 
 
Mortality was 3.42 times more common in the diabetic 
population compared to non diabetic. 
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TABLE - 16 
DISTRIBUTION ACCORDING TO THROMBOLYSIS STATUS 
 
Thrombolysis  
Group 
Yes No 
Total 
Diabetic  100 13 113 
Non Diabetic 380 26 406 
 
P value =  0.069   Not significant  
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Discussion   
DISCUSSION 
Out of the 519 cases of myocardial infarction in this study, 
113 cases were diabetics and 406 cases were non diabetics. 
There were 7 cases of myocardial infarction under the age of 
30 years in the non diabetic group compared to none in the diabetic 
group. 
Between 31 to 50 years the incidence of myocardial infarction 
was more common in the non diabetic group compared to diabetic 
group. 
Above the age of 50 years the incidence of myocardial 
infarction was higher in the diabetic population. Even though there 
was a slight increase in the age of occurrence of myocardial 
infarction among the diabetic patients compared to nondiabetics, it 
was not statically significant. 
Percentage of female patients with myocardial infarction in 
the diabetic group was 29.20% when compared to 16.25% in non 
diabetic group. This is well in correlation with study of Stone P H 
et al (14). 
42.8% of the patients in the diabetic group had sedentary life 
style compared to 27.5% of patients in non diabetic group. 
It was found that the incidence of painless myocardial 
infarction were 7.16 times more common in the diabetic group 
compared to non diabetics (P<0.001). 
Most of the patients in the diabetic group were having a 
duration of diabetes less than five years and only 50 percentage of 
these diabetics were under regular treatment. 
Diabetic group showed higher Killip class when compared to 
non diabetic group. The incidence of congestive cardiac failure was 
5.83 times to that of non diabetics (P<0.001). The incidence of 
cardiogenic shock was also higher in the diabetic group. The 
ejection fraction in diabetic group was very low compared to non 
diabetics. 8.82% of diabetics had an ejection fraction less than 40% 
when compared to only 0.51% in non diabetics. 
Diabetic patients showed a higher incidence of anterior wall 
myocardial infarction compared to non diabetics. They had 3.79 
times more chance to have anterior wall myocardial infarction 
compared to non diabetics (P<0.001). 
The presence of complete heart blocks and life threatening 
ventricular arrhythmias were also higher in diabetics. The 
incidence of ventricular arrhythmias in diabetic group was 4.40 
times that of non diabetic group. 
The mortality due to myocardial infarction among diabetic 
group was 3.42 times that of non diabetic group. 
  
 
 
 
 
 
 
 
 
 
Conclusion  
CONCLUSION 
9 In this study, there was no significant difference in the age 
of occurrence of myocardial infarction among diabetic and 
nondiabetic group. 
9 Women with diabetes lost most of the inherent protection 
against coronary artery disease when compared to non 
diabetics.   
9 Painless myocardial infarctions were far more common in 
diabetics compared to nondiabetics. 
9 Anterior wall myocardial infarctions were common and 
ejection fractions were consistently lower among diabetics. 
9 Congestive cardiac failure and cardiogenic shock were more 
common and severe in subjects with diabetes than non 
diabetics. This was more than to be expected from the size 
of the infarction. 
9 Complications of myocardial infarction like life threatening 
ventricular arrhythmias and complete heart blocks were far 
more common among diabetics compared to non diabetics. 
9 In hospital mortality due to myocardial infarction in 
diabetics were three to four times higher that of non 
diabetics. 
 
  
 
 
 
 
 
 
 
 
 
Summary 
SUMMARY 
The present study was conducted over a period two years 
among patients admitted with ST elevation myocardial infarction 
in the cardiology department of Kilpauk Medical College. Patients 
were divided into diabetic and non diabetic groups. With 
application of inclusion as well as exclusion criteria 113 diabetics 
and 406 nondiabetics were chosen for the study. Findings of the 
study are as follows: 
1. There was no significant difference in the age of occurrence of 
myocardial infarction among diabetic and non diabetic group 
(p value > 0.05). 
2. The percentage of females in diabetic group were far more 
compared to non diabetic group. (diabetic =29.20%, non 
diabetic =16.25%). 
3. The diabetic group had more sedentary life style compared to 
non diabetics. (diabetic =42.48%, non diabetic =27.40% ) 
4. Painless myocardial infarctions were 7 times more common 
in diabetic group. (odds ratio = 7.16 ) (P value < 0.001). 
5. Most of the patients in the diabetic group were detected to 
have diabetes over the last five years (61.95 %). 
6. Diabetic patients with myocardial infarction showed a 
preponderance to anterior wall compared to non diabetics. 
(Odds ratio = 3.79). 
7. Cardiac failure was about six times more common in the 
diabetic group  (Odds ratio = 5.83) (P<0.001). 
8. Complications of myocardial infarctions were also common in 
diabetic group (ventricular arrhythmia- odds ratio = 4.40, 
complete heart block) (P<0.001).  
9. Mortality due to myocardial infarction in diabetic group was 
about four times that of non diabetic group. (odds ratio = 
3.42) 
10. No significant time difference in receiving thrombolysis was 
noticed in the two groups (P>0.05).  
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ABBREVIATIONS 
ADP  - Adenosine Diposphate 
AGEs  - Advancedglycation End Products 
ALMI  -  Anterolateral MI 
ASMI  -  Anteroseptal MI 
AWMI  -  Extensive Anterior Wall MI  
BP  -  Blood Pressure 
CAD  -  Coronary Artery Disease  
CK-MB  - Creatine Kinase - MB 
CML  -  Carboxymethyllysine 
CVS  -  Cardiovascular System 
ECG  -  Electrocardiography 
EDRF  -  Endothelium Derived Relaxing Factor 
EF  -  Ejection Fraction 
F  -  Female 
FBS  -  Fasting Blood Sugar 
GOD  -  Glucose Oxidase 
HDL  -  High Density Lipoprotein 
IWMI  -  Inferior Wall MI 
LDL  - Low Density Lipoprotein 
M  -  Male 
M I  -  Myocardial Infarction 
ML  -  Manual Labourer 
No. - Number 
PAI-1  - Plasminogen Activator Inhibitor-1 
POD  - Peroxidase 
PWMI  -  Posterior Wall MI 
RBS  -  Random Blood Sugar 
S  -  Sedentary 
STEMI  - ST-Elevation Myocardial Infarction 
t-PA  -  tissue Plasminogen Activator 
VLDL  -  Very Low Density Lipoprotein 
 
PROFORMA 
 
NAME :        
AGE : 
SEX :         M/F     DOA :   
OCCUPATION :- M L/ S   DOD : 
 
SYMPTOMS 
CHIEF PRESENTING COMPLAINT: 
 CHEST PAIN 
 BREATHLESSNESS 
 PALPITATION 
 SYNCOPE 
 NONE OF THE ABOVE 
 
DIABETIC : Y/N 
 DURATION :  <5yrs 
5 – 10 yrs 
    10 – 15 yrs 
    >15 yrs 
 
TREATMENT:-  Regular / Irregular 
 
CLINICAL EXAMINATION 
 PULSE 
 BP 
 KILLIP Class. 
 CVS 
 
INVESTIGATION 
 FBS 
 RBS 
 ECG :-  Extensive Anterior Wall (AWMI) 
    Anteroseptal Wall (ASMI) 
    Anterolateral Wall (ALMI) 
    Inferior Wall (IWMI) 
 
 ECHO  
  Wall involved - 
  Ejection Fraction - 
COMPLICATION 
 CARDIAC FAILURE – Yes / No 
 LIFE THREATENING ARRYTHMIA – Yes / No 
 PERICARDITIS – Yes / No 
 THROMBOEMBOLISM – Yes / No 
 PAPILLARY MUSCLE DYSFN. – Yes / No 
 VENTRICULAR SEPTAL RUPTURE – Yes / No 
DEATH:- Yes/ No  
 
 
MASTER CHART 
                
S.No Age Sex Occ. 
P 
Com. DM Dur. Rx P K C FBS RBS ECG EF Comp Mort 
1 65 F S CP - - - 82 II 78 120 ASMI 60 CCF - 
2 62 F S CP - - - 60 I 90 110 IWMI 60 - - 
3 61 F S CP - - - 88 I 80 90 ALMI 6O - - 
4 35 M M CP - - - 80 I 74 86 ASMI 54 - - 
5 46 M M CP -     - - 76 I 80 120 ASMI 60 - - 
6 44 M S CP - - - 80 I 80 100 ASMI 60 - - 
7 60 M M CP - - - 80 I 64 124 AWMI 50 - - 
8 48 M M CP - - - 90 I 80 125 ASMI 60 - - 
9 70 M S CP - - - 84 I 110 136 ASMI 60 - - 
10 48 M M CP - - - 90 I 70 100 ALMI 60 - - 
11 59 F M CP - - - 80 I 74 128 IWMI 62 - - 
12 54 M M CP - - - 86 I 88 100 IWMI 60 - - 
13 78 M M CP - - - 92 I 80 96 ASMI 60 - - 
14 48 M M CP - - - 100 I 100 160 ASMI 60 - - 
15 30 M  M CP - - - 80 I 68 120 IWMI 60 - - 
16 45 M M CP - - - 77 I 74 129 AWMI 60 - - 
17 74 M M CP - - - 60 I 88 112 ASMI 60 - - 
18 42 M M CP - - - 70 I 80 120 IWMI 60 - - 
19 42 M M CP - - - 84 I 66 86 ASMI 60 - - 
20 55 M M CP - - - 66 I 80 100 AWMI 50 CCF - 
21 56 M M CP - - - 80 I 78 99 IWMI 60 - - 
22 50 M M CP - - - - IV     AWMI   CCF + 
23 47 M M CP - - - 90 IV     ALMI   CCF       + 
24 74 M M CP - - - 60 I 106 165 IWMI 60 - - 
25 46 M M CP - - - 92 I 80 100 IWMI 60 - - 
26 35 M M CP - - - 80 I 108 128 ASMI 56 - - 
27 42 M M CP - - - 80 I 66 78 ALMI 48 CCF - 
28 68 M M CP - - - 180 I 60 74 ALMI 50 VT - 
29 53 M M CP - - - 98 I 100 180 ASMI 57 - - 
30 79 M M SY - - - 90 III 60 68 ALMI 50 CCF - 
31 40 M M CP - - - 70 II 80 120 ASMI 54 CCF - 
32 67 M M CP - - - 96 II 106 192 AWMI 50 CCF - 
33 59 F M BR - - - 60 II 100 136 AWMI 35 CCF,CHB + 
34 42 M M CP - - - 80 I 69 98 ASMI 60 - - 
35 60 M M CP - - - 76 I 66 88 ASMI 60 - - 
36 43 M M CP - - - 76 I 74 100 IWMI 57 - - 
37 45 M S CP - - - 70 I 64 110 ASMI 60 - - 
38 47 M M CP - - - 80 I 76 108 IWMI 56 - - 
39 40 M M CP - - - 66 I 88 126 IWMI 60 - - 
40 44 M S CP - - - 70 II 74 116 IWMI 47 CCF + 
41 60 M M CP - - - 90 I 90 138 PWMI 56 - - 
42 44 M M CP - - - 86 I 76 98 IWMI 60 - - 
43 43 M M CP - - - 88 I 66 104 IWMI 60 - - 
44 52 M M CP - - - 98 I 77 140 AWMI 54 - - 
45 70 M M CP - - - 70 I 86 140 ASMI 56 - - 
46 57 M M CP - - - 70 I 74 98 ASMI 56 - - 
47 50 M M CP - - - 90 I 64 80 ASMI 58 - - 
48 60 M M CP - - - 90 I 90 76 IWMI 60 - - 
49 50 M M CP - - - 60 I 70 90 IWMI 60 - - 
50 55 M M CP - - - 90 I 74 118 ASMI 59 - - 
51 56 M M BR - - - 110 IV     AWMI   CCF + 
52 34 M M CP - - - 86 I 66 78 ASMI 54 - - 
53 44 M M CP - - - 88 I 68 78 IWMI 58 - - 
54 54 F S CP - - - 70 I 98 130 IWMI 58 - - 
55 65 F S CP - - - 80 I 90 130 IWMI 60 - - 
56 34 M S CP - - - 80 II 54 77 ASMI 48 CCF - 
57 54 M M BR - - - 110 IV     AWMI   CCF + 
58 42 M S CP - - - 90 I 98 120 AWMI 50 - - 
59 37 F S CP - - - 70 I 78 116 IWMI 58 - - 
60 60 M M CP - - - 88 I 78 68 ASMI 58 - - 
61 42 M S CP - - - 70 I 70 109 IWMI 60 - - 
62 67 M M BR - - - 70 IV     AWMI   CCF + 
63 42 M M CP - - - 90 I 68 79 ASMI 56 - - 
64 58 M M CP - - - 90 I 90 130 IWMI 50 - - 
65 54 M M CP - - - 80 I 84 118 IWMI 60 - - 
66 42 M S CP - - - 90 I 78 106 IWMI 58 - - 
67 72 M M CP - - - 90 I 88 120 IWMI 60 - - 
68 37 M M BR - - - 100 IV     ASMI   CCF VF + 
69 75 M S CP - - - 80 I 66 99 IWMI 60 - - 
70 50 M M CP - - - 90 I 88 100 IWMI 58 - - 
71 42 M M CP - - - 80 I 80 110 IWMI 60 - - 
72 55 M M CP - - - 80 I 86 120 IWMI 60 - - 
73 75 F S CP - - - 80 I 76 94 ASMI 56 - - 
74 34 M S CP - - - 90 I 76 98 IWMI 60 - - 
75 57 M M CP - - - 66 I 90 130 ASMI 58 - - 
76 67 M M CP - - - 100 I 68 110 ASMI 56 - - 
77 65 M M CP - - - 80 I 60 80 IWMI 60 - - 
78 38 M S CP - - - 8O I 86 120 ASMI 60 - - 
79 74 M S CP - - - 90 I 100 168 ASMI 56 - - 
80 65 M M CP - - - 80 I 77 106 AWMI 52 VT - 
81 45 M M CP - - - 90 I 88 90 ASMI 60 - - 
82 67 F M CP - - - 80 I 66 90 ASMI 58 - - 
83 43 M M CP - - - 82 I 90 120 AWMI 54 - - 
84 38 M S CP - - - 90 I 90 130 ASMI 60 - - 
85 50 M M CP - - - 80 I 77 110 ASMI 60 - - 
86 53 M S CP - - - 80 I 66 78 ASMI 60 - - 
87 70 M M CP - - - 90 I 60 96 ASMI 58 - - 
88 52 M M CP - - - 90 I 90 136 ASMI 58 - - 
89 36 M M CP - - - 80 I 90 132 ASMI 60 - - 
90 50 F S CP - - - 110 I 110 160 ALMI 60         - - 
91 43 M M C P - - - 80 I 88 112 IWMI 60 - - 
92 66 M S CP - - - 80 I 70 110 IWMI 60 - - 
93 70 M M CP -      - - 80 I 70 110 IWMI 60 - - 
94 53 M M CP - - - 80 I 90 130 ASMI 56 - - 
95 47 M M CP - - - 92 I 56 70 ASMI 60 - - 
96 48 M S CP - - - 92 I 90 120 ASMI 60 - - 
97 37 F S CP - - - 92 I 74 110 ASMI 58 - - 
98 35 M M CP - - - 80 I 86 110 IWMI 60 - - 
99 43 M M CP - - - 88 I 99 130 AWMI 54 - - 
100 68 M M CP - - - 86 I 70 100 ASMI 60 - - 
101 70 M M CP - - - 80 I 88 100 IWMI 60 - - 
102 65 F M CP - - - 90 I 74 90 ASMI 60 - - 
103 65 F S CP - - - 60 I 70 86 ASMI 57 - - 
104 50 M M CP - - - 76 I 66 86 ALMI 60 - - 
105 40 M M CP - - - 90 I 90 108 IWMI 60 - - 
106 45 M M CP - - - 80 I 80 64 AWMI 59 - - 
107 62 M M CP - - - 71 I 76 104 ASMI 60 - - 
108 54 M S CP - - - 82 I 58 60 ASMI 59 - - 
109 37 M S CP - - - 76 I 80 152 IWMI 60 - - 
110 52 M M CP - - - 74 I 64 88 ASMI 60 - - 
111 54 M M CP - - - 80 I 60 110 ASMI 58 - - 
112 45 M S CP - - - 100 I     80 105 ALMI 60 - - 
113 50 M M CP - - - 70 I 66 106 IWMI 60 - - 
114 47 M M CP - - - 90 I 70 68 ALMI 60 - - 
115 83 M S CP - - - 80 I 70 110 ALMI 60 - - 
116 53 M M CP - - - 72 I 98 100 IWMI 57 - - 
117 40 M M CP - - - 94 I 80 101 IWMI 60 - - 
118 45 M M CP - - - 80 I 80 100 IWMI 60 - - 
119 80 F S CP - - - 92 I 80 110 IWMI 60 - - 
120 65 F M CP - - - 92 I 70 88 ASMI 56 - - 
121 69 F S CP - - - 68 I 100 180 ALMI 57 - - 
122 78 F S CP - - - 100 I 90 135 ASMI 57 - - 
123 60 F S CP - - - 86 I 70 114 ASMI 60 - - 
124 63 M M CP - - - 80 I 70 72 IWMI 60 - - 
125 40 F S CP - - - 80 I 90 116 IWMI 60 - - 
126 50 M M CP - - - 68 I 80 130 IWMI 60 - - 
127 58 M S CP - -     -    110 I 100 110 IWMI 60 - - 
128 34 M M CP - - - 90 I 90 104 IWMI 60 - - 
129 55 M M     CP - - - 80 I 90 160 AWMI 60 - - 
130 60 M M CP - - - 80 I 60 75 ASMI 60 - - 
131 27 M S CP - - - 80 I 66 100 IWMI 60 - - 
132 60 M M CP - - - 80 I 60 78 ASMI 58 - - 
133 57 M M CP - - - 62 I 78 98 ASMI 60 - - 
134 68 M M CP - - - 80    I 90 127 ASMI 60 - - 
135 49 M M CP - - - 88 I 70 50 ASMI 60 - - 
136 65 M M CP - - - 90 I 90 170 ASMI 60 - - 
137 70 M M CP - - - 89 I 70 88 ASMI 60 - - 
138 45 M M CP - - - 87 I 68 110 IWMI 60 - - 
139 39 M M CP - - - 92 I 80 78 IWMI 60 - - 
140 56 M M CP - - - 84 II 80 110 ASMI 56 CCF - 
141 52 M M CP - - - 54 I 90 130 IWMI 58 - - 
142 45 F S CP - - - 80 I 66 119 AWMI 60 - - 
143 74 M M CP - - - 85 I 68 75 IWMI 58 - - 
144 70 M M CP - - - 76 I 78 120 ASMI 56 - - 
145 50 M M CP - - - 66 I 76 94 ALMI 58 - - 
146 68 M M CP - - - 92 I 100 176 ASMI 58 - - 
147 44 M M CP - - - 86 I 76 120 ASMI 60 - - 
148 38 M M CP - - - 98 I 97 164 IWMI 60 - - 
149 52 M M CP - - - 118 I 98 120 IWMI 60 - - 
150 37 F S CP - - - 86 I 70 98 ALMI 60 - - 
151 52 M M CP - - - 86 I 66 83 ASMI 58 - - 
152 76 M M CP - - - 80 I 88 110 IWMI 54 - - 
153 38 M S CP - - - 94 I 98 124 IWMI 60 - - 
154 45 M M CP - - - 86 I 77 102 AWMI 58 - - 
155 70 M M CP - - - 87 I 90 180 AWMI 56 - - 
156 53 M M CP - - - 60 I 96 150 IWMI 56 - - 
157 51 M M CP -     - - 64 I 98 188 ASMI 60 - - 
158 55 F S CP - - - 82 I 75 128 IWMI 60 - - 
159 55 F S CP - - - 86 I 52 71 IWMI 58 - - 
160 62 F S CP - - - 106 II 64 70 AWMI 56 CCF - 
161 51 F M CP - - - 82 I 96 192 ASMI 60 - - 
162 74 M S  CP - - - 88 I 96 110 ASMI 58 - - 
163 41 M M CP - - - 102 I 60 58 IWMI 60 - - 
164 59 M M CP - - - 64 I 54 75 ASMI 56 - - 
165 53 M M CP - - - 92 I 66 60 IWMI 60 - - 
166 56 M M CP - - - 92 I 68 54 IWMI 60 - - 
167 72 M M CP - - - 70 I 66 91 ASMI 60 - - 
168 56 M M CP - - - 66 I 76 90 ASMI 60 - - 
169 40 M M CP - - - 100 I 56 60 IWMI 60 - - 
170 49 M M CP - - - 104 II 64 90 AWMI 50 CCF - 
171 40 M M CP - - - 100 I 68 99 IWMI 60 - - 
172 39 M S CP - - - 62 I 65 125 IWMI 60 - - 
173 41 M M CP - - - 70 I 96 128 IWMI 60 - - 
174 48 M M CP - - - 84 I 68 76 IWMI 60 - - 
175 50 M M CP - - - 57 I 76 120 IWMI 60 - - 
176 35 M S CP - - - 82 I 56 65 IWMI 58 - - 
177 28 M S CP - - - 92 I 96 125 ASMI 60 - - 
178 56 M M CP - - - 120 I 90 176 ASMI 60 - - 
179 55 F M CP - - - 78 I 99 140 ALMI 60 - - 
180 60 F S CP - - - 88 I 76 88 IWMI 60 - - 
181 38 F S CP - - - 76 I 86 89 IWMI 60 - - 
182 60 M M CP - - - 76 I 80 100 IWMI 60 - - 
183 60 M S SY - - - 72 I 110 194 ASMI 60 - - 
184 58 M M CP - - - 56 I 87 116 IWMI 57 - - 
185 74 M M CP - - - 66 I 56 78 IWMI 58 - - 
186 65 F S CP - - - 88 I 98 104 IWMI 60 - - 
187 46 M S CP - - - 68 I 67 93 ASMI 58 - - 
188 54 M M CP - - - 76 I 90 124 ASMI 60 - - 
189 67 M M CP - - - 80 I 98 110 ASMI 56 - - 
190 54 F S CP - - - 64 I 67 88 ASMI 60 - - 
191 56 M M CP - - - 92 I 68 54 IWMI 60 - - 
192 72 M M CP - - - 70 I 66 91 ASMI 60 - - 
193 56 M M CP - - - 66 I 76 90 ASMI 60 - - 
194 40 M M CP - - - 100 I 56 60 IWMI 60 - - 
195 49 M M CP - - - 104 II 64 90 AWMI 50 CCF - 
196 40 M M CP - - - 100 I 68 99 IWMI 60 - - 
197 39 M S CP - - - 62 I 65 125 IWMI 60 - - 
198 41 M M CP - - - 70 I 96 128 IWMI 60 - - 
199 48 M M CP - - - 84 I 68 76 IWMI 60 - - 
200 50 M M CP - - - 57 I 76 120 IWMI 60 - - 
201 35 M S CP - - - 82 I 56 65 IWMI 58 - - 
202 28 M S CP - - - 92 I 96 125 ASMI 60 - - 
203 56 M M CP - - - 120 I 90 176 ASMI 60 - - 
204 55 F M CP - - - 78 I 99 140 ALMI 60 - - 
205 60 F S CP - - - 88 I 76 88 IWMI 60 - - 
206 38 F S CP - - - 76 I 86 89 IWMI 60 - - 
207 60 M M CP - - - 76 I 80 100 IWMI 60 - - 
208 60 M S SY - - - 72 I 110 194 ASMI 60 - - 
209 58 M M CP - - - 56 I 87 116 IWMI 57 - - 
210 74 M M CP - - - 66 I 56 78 IWMI 58 - - 
211 65 F S CP - - - 88 I 98 104 IWMI 60 - - 
212 46 M S CP - - - 68 I 67 93 ASMI 58 - - 
213 54 M M CP - - - 76 I 90 124 ASMI 60 - - 
214 67 M M CP - - - 80 I 98 110 ASMI 56 - - 
215 54 F S CP - - - 64 I 67 83 IWMI 60 - - 
216 53 M M CP - - - 92 I 66 60 IWMI 60 - - 
217 42 M M CP - - - 80 I 66 78 ALMI 48 CCF - 
218 70 M M CP - - - 87 I 90 180 AWMI 56 - - 
219 68 M M CP - - - 180 I     ALMI   VF + 
220 53 M M CP - - - 98 I 100 180 ASMI 57 - - 
221 79 M M SY - - - 90 III 60 68 ALMI 50 CCF - 
222 40 M M CP - - - 70 II 80 120 ASMI 54 CCF - 
223 67 M M CP - - - 96 II 106 192 AWMI 50 CCF - 
224 59 F M BR - - - 60 II 100 136 AWMI 35 CCF CHB + 
225 42 M M CP - - - 80 I 69 98 ASMI 60 - - 
226 60 M M CP - - - 76 I 66 88 ASMI 60 - - 
227 43 M M CP - - - 76 I 74 100 IWMI 57 - - 
228 45 M S CP - - - 70 I 64 110 ASMI 60 - - 
229 47 M M CP - - - 80 I 76 108 IWMI 56 - - 
230 40 M M CP - - - 66 I 88 126 IWMI 60 - - 
231 44 M S CP - - - 70 II 74 116 IWMI 47 CCF + 
232 60 M M CP - - - 90 I 90 138 PWMI 56 - - 
233 44 M M CP - - - 86 I 76 98 IWMI 60 - - 
234 43 M M CP - - - 88 I 66 104 IWMI 60 - - 
235 52 M M CP - - - 98 I 77 140 AWMI 54 - - 
236 70 M M CP - - - 70 I 86 140 ASMI 56 - - 
237 57 M M CP - - - 70 I 74 98 ASMI 56 - - 
238 50 M M CP - - - 90 I 64 80 ASMI 58 - - 
239 60 M M CP - - - 90 I 90 76 IWMI 60 - - 
240 50 M M CP - - - 60 I 70 90 IWMI 60 - - 
241 55 M M CP - - - 90 I 74 118 ASMI 59 - - 
242 56 M M BR - - - 110 IV     AWMI   CCF VF + 
243 34 M M CP - - - 86 I 66 78 ASMI 54 - - 
244 44 M M CP - - - 88 I 68 78 IWMI 58 - - 
245 54 F S CP - - - 70 I 98 130 IWMI 58 - - 
246 65 F S CP - - - 80 I 90 130 IWMI 60 - - 
247 34 M S CP - - - 80 II 54 77 ASMI 48 CCF - 
248 54 M M BR - - - 110 IV     AWMI   CCF + 
249 42 M S CP - - - 90 I 98 120 AWMI 50 - - 
250 37 F S CP - - - 70 I 78 116 IWMI 58 - - 
251 60 M M CP - - - 88 I 78 68 ASMI 58 - - 
252 42 M S CP - - - 70 I 70 109 IWMI 60 - - 
253 67 M M BR - - - 70 IV     AWMI   CCF + 
254 42 M M CP - - - 90 I 68 79 ASMI 56 - - 
255 58 M M CP - - - 90 I 90 130 IWMI 50 - - 
256 54 M M CP - - - 80 I 84 118 IWMI 60 - - 
257 42 M S CP - - - 90 I 78 106 IWMI 58 - - 
258 72 M M CP - - - 90 I 88 120 IWMI 60 - - 
259 37 M M BR - - - 100 IV     ASMI   CCF + 
260 75 M S CP - - - 80 I 66 99 IWMI 60 - - 
261 50 M M CP - - - 90 I 88 100 IWMI 58 - - 
262 42 M M CP - - - 80 I 80 110 IWMI 60 - - 
263 55 M M CP - - - 80 I 86 120 IWMI 60 - - 
264 75 F S CP - - - 80 I 76 94 ASMI 56 - - 
265 34 M S CP - - - 90 I 76 98 IWMI 60 - - 
266 57 M M CP - - - 66 I 90 130 ASMI 58 - - 
267 67 M M CP - - - 100 I 68 110 ASMI 56 - - 
268 65 M M CP - - - 80 I 60 80 IWMI 60 - - 
269 38 M S CP - - - 8O I 86 120 ASMI 60 - - 
270 74 M S CP - - - 90 I 100 168 ASMI 56 - - 
271 65 M M CP - - - 80 I 77 106 AWMI 52 VT - 
272 45 M M CP - - - 90 I 88 90 ASMI 60 - - 
273 67 F M CP - - - 80 I 66 90 ASMI 58 - - 
274 43 M M CP - - - 82 I 90 120 AWMI 54 - - 
275 38 M S CP - - - 90 I 90 130 ASMI 60 - - 
276 50 M M CP - - - 80 I 77 110 ASMI 60 - - 
277 53 M S CP - - - 80 I 66 78 ASMI 60 - - 
278 70 M M CP - - - 90 I 60 96 ASMI 58 - - 
279 52 M M CP - - - 90 I 90 136 ASMI 58 - - 
280 36 M M CP - - - 80 I 90 132 ASMI 60 - - 
281 50 F S CP - - - 110 I 110 160 ALMI 60         - - 
282 43 M M C P - - - 80 I 88 112 IWMI 60 - - 
283 66 M S CP - - - 80 I 70 110 IWMI 60 - - 
284 70 M M CP -      - - 80 I 70 110 IWMI 60 - - 
285 53 M M CP - - - 80 I 90 130 ASMI 56 - - 
286 47 M M CP - - - 92 I 56 70 ASMI 60 - - 
287 48 M S CP - - - 92 I 90 120 ASMI 60 - - 
288 37 F S CP - - - 92 I 74 110 ASMI 58 - - 
289 35 M M CP - - - 80 I 86 110 IWMI 60 - - 
290 43 M M CP - - - 88 I 99 130 AWMI 54 - - 
291 68 M M C P - - - 86 I 70 100 ASMI 60 - - 
292 70 M M CP - - - 80 I 88 100 IWMI 60 - - 
293 65 F M CP - - - 90 I 74 90 ASMI 60 - - 
294 65 F S CP - - - 60 I 70 86 ASMI 57 - - 
295 50 M M CP - - - 76 I 66 86 ALMI 60 - - 
296 40 M M CP - - - 90 I 90 108 IWMI 60 - - 
297 45 M M CP - - - 80 I 80 64 AWMI 59 - - 
298 62 M M CP - - - 71 I 76 104 ASMI 60 - - 
299 54 M S CP - - - 82 I 58 60 ASMI 59 - - 
300 37 M S CP - - - 76 I 80 152 IWMI 60 - - 
301 52 M M CP - - - 74 I 64 88 ASMI 60 - - 
302 54 M M CP - - - 80 I 60 110 ASMI 58 - - 
303 45 M S CP - - - 100 I    80 105 ALMI 60 - - 
304 50 M M CP - - - 70 I 66 106 IWMI 60 - - 
305 47 M M CP - - - 90 I 70 68 ALMI 60 - - 
306 83 M S CP - - - 80 I 70 110 ALMI 60 - - 
307 53 M M CP - - - 72 I 98 100 IWMI 57 - - 
308 40 M M CP - - - 94 I 80 101 IWMI 60 - - 
309 45 M M CP - - - 80 I 80 100 IWMI 60 - - 
310 80 F S CP - - - 92 I 80 110 IWMI 60 - - 
311 65 F M CP - - - 92 I 70 88 ASMI 56 - - 
312 69 F S CP - - - 68 I 100 180 ALMI 57 - - 
313 78 F S CP - - - 100 I 90 135 ASMI 57 - - 
314 60 F S CP - - - 86 I 70 114 ASMI 60 - - 
315 63 M M CP - - - 80 I 70 72 IWMI 60 - - 
316 40 F S CP - - - 80 I 90 116 IWMI 60 - - 
317 50 M M CP - - - 68 I 80 130 IWMI 60 - - 
318 58 M S CP - -     -    110 I 100 110 IWMI 60 - - 
319 34 M M CP - - - 90 I 90 104 IWMI 60 - - 
320 55 M M   CP - - - 80 I 90 160 AWMI 60 - - 
321 60 M M CP - - - 80 I 60 75 ASMI 60 - - 
322 27 M S CP - - - 80 I 66 100 IWMI 60 - - 
323 60 M M CP - - - 80 I 60 78 ASMI 58 - - 
324 57 M M CP - - - 62 I 78 98 ASMI 60 - - 
325 68 M M CP - - - 80 I    90 127 ASMI 60 - - 
326 49 M M CP - - - 88 I 70 50 ASMI 60 - - 
327 65 M M CP - - - 90 I 90 170 ASMI 60 - - 
328 70 M M CP - - - 89 I 70 88 ASMI 60 - - 
329 45 M M CP - - - 87 I 68 110 IWMI 60 - - 
330 39 M M CP - - - 92 I 80 78 IWMI 60 - - 
331 56 M M CP - - - 84 II 80 110 ASMI 56 CCF - 
332 52 M M CP - - - 54 I 90 130 IWMI 58 - - 
333 45 F S CP - - - 80 I 66 119 AWMI 60 - - 
334 74 M M CP - - - 85 I 68 75 IWMI 58 - - 
335 70 M M CP - - - 76 I 78 120 ASMI 56 - - 
336 50 M M CP - - - 66 I 76 94 ALMI 58 - - 
337 68 M M CP - - - 92 I 100 176 ASMI 58 - - 
338 44 M M CP - - - 86 I 76 120 ASMI 60 - - 
339 38 M M CP - - - 98 I 97 164 IWMI 60 - - 
340 52 M M CP - - - 118 I 98 120 IWMI 60 - - 
341 37 F S CP - - - 86 I 70 98 ALMI 60 - - 
342 52 M M CP - - - 86 I 66 83 ASMI 58 - - 
343 76 M M CP - - - 80 I 88 110 IWMI 54 - - 
344 38 M S CP - - - 94 I 98 124 IWMI 60 - - 
345 45 M M CP - - - 86 I 77 102 AWMI 58 - - 
346 53 M M CP - - - 60 I 96 150 IWMI 56 - - 
347 51 M M CP -     - - 64 I 98 188 ASMI 60 - - 
348 55 F S CP - - - 82 I 75 128 IWMI 60 - - 
349 55 F S CP - - - 86 I 52 71 IWMI 58 - - 
350 62 F S CP - - - 106 II 64 70 AWMI 56 CCF - 
351 51 F M CP - - - 82 I 96 192 ASMI 60 - - 
352 74 M S  CP - - - 88 I 96 110 ASMI 58 - - 
353 41 M M CP - - - 102 I 60 58 IWMI 60 - - 
354 59 M M CP - - - 64 I 54 75 ASMI 56 - - 
355 65 F S CP - - - 82 II 78 120 ASMI 60 CCF - 
356 62 F S CP - - - 60 I 90 110 IWMI 60 - - 
357 61 F S CP - - - 88 I 80 90 ALMI 6O - - 
358 35 M M CP - - - 80 I 74 86 ASMI 54 - - 
359 46 M M CP -     - - 76 I 80 120 ASMI 60 - - 
360 44 M S CP - - - 80 I 80 100 ASMI 60 - - 
361 60 M M CP - - - 8O I 64 124 AWMI 50 - - 
362 48 M M CP - - - 90 I 80 125 ASMI 60 - - 
363 70 M S CP - - - 84 I 110 136 ASMI 60 - - 
364 48 M M CP - - - 90 I 70 100 ALMI 60 - - 
365 59 F M CP - - - 80 I 74 128 IWMI 62 - - 
366 54 M M CP - - - 86 I 88 100 IWMI 60 - - 
367 78 M M CP - - - 92 I 80 96 ASMI 60 - - 
368 48 M M CP - - - 100 I 100 160 ASMI 60 - - 
369 30 M M CP - - - 80 I 68 120 IWMI 60 - - 
370 45 M M CP - - - 77 I 74 129 AWMI 60 - - 
371 74 M M CP - - - 60 I 88 112 ASMI 60 - - 
372 42 M M CP - - - 70 I 80 120 IWMI 60 - - 
373 42 M M CP - - - 84 I 66 86 ASMI 60 - - 
374 55 M M CP - - - 66 I 80 100 AWMI 50 CCF - 
375 56 M M CP - - - 80 I 78 99 IWMI 60 - - 
376 50 M M CP - - - 64 IV     AWMI   CCF + 
377 47 M M CP - - - 90 IV     ALMI   CCF + 
378 74 M M CP - - - 60 I 106 165 IWMI 60 - - 
379 46 M M CP - - - 92 I 80 100 IWMI 60 - - 
380 35 M M CP - - - 80 I 108 128 ASMI 56 - - 
381 65 F S CP - - - 82 II 78 120 ASMI 60 CCF - 
382 62 F S CP - - - 60 I 90 110 IWMI 60 - - 
383 61 F S CP - - - 88 I 80 90 ALMI 6O - - 
384 35 M M CP - - - 80 I 74 86 ASMI 54 - - 
385 46 M M CP -  - - 76 I 80 120 ASMI 60 - - 
386 44 M S CP - - - 80 I 80 100 ASMI 60 - - 
387 60 M M CP - - - 8O I 64 124 AWMI 50 - - 
388 48 M M CP - - - 90 I 80 125 ASMI 60 - - 
389 70 M S CP - - - 84 I 110 136 ASMI 60 - - 
390 48 M M CP - - - 90 I 70 100 ALMI 60 - - 
391 59 F M CP - - - 80 I 74 128 IWMI 62 - - 
392 54 M M CP - - - 86 I 88 100 IWMI 60 - - 
393 78 M M CP - - - 92 I 80 96 ASMI 60 - - 
394 48 M M CP - - - 100 I 100 160 ASMI 60 - - 
395 30 M M    CP - - - 80 I 68 120 IWMI 60 - - 
396 45 M M CP - - - 77 I 74 129 AWMI 60 - - 
397 74 M M CP - - - 60 I 88 112 ASMI 60 - - 
398 42 M M CP - - - 70 I 80 120 IWMI 60 - - 
399 42 M M CP - - - 84 I 66 86 ASMI 60 - - 
400 55 M M CP - - - 66 I 80 100 AWMI 50 CCF - 
401 56 M M CP - - - 80 I 78 99 IWMI 60 - + 
402 50 M M CP - - - 76 IV     AWMI   CCF + 
403 47 M M CP - - - 90 IV     ALMI   CCF + 
404 74 M M CP - - - 60 I 106 165 IWMI 60 - - 
405 46 M M CP - - - 92 I 80 100 IWMI 60 - - 
406 35 M M CP - - - 80 I 108 128 ASMI 56 - - 
407 46 M S CP + 3 IR 98 IV     AWMI   CCF + 
408 58 F S CP + 7 IR 92 I     IWMI   VF + 
409 65 F M CP + 8 R 80 I 186 320 ASMI 56 - - 
410 58 F M CP + 8 R 90 II 130 188 ASMI 54 CCF - 
411 60 F S CP + 4 R 86 I 168 200 ASMI 60 - - 
412 51 M M CP + 3 IR 52 I 200 390 ASMI 60 - - 
413 35 F S CP + 3 IR 80 I 219 300 ASMI 56 - - 
414 65 M M CP + 4 R 88 I 130 170 ASMI 60 - - 
415 49 F S CP + 1 R 90 I 88 168 ALMI 60 - - 
416 48 M M CP + 7 IR 80 I 260 384 ASMI 60 - - 
417 55 M M BR + 9 R 100 III 96 118 AWMI 45 CCF - 
418 65 M M BR + 4 R 110 III     AWMI 30 CCF,VF + 
419 37 M S CP + 3 IR 80 I 168 204 ASMI 50 - - 
420 52 M M BR + 8 R 90 II 140 210 AWMI 44 CCF - 
421 40 M S BR + 4 IR 96 II 198 278 AWMI 36 CCF - 
422 34 M S CP + 3 R 90 I 288 348 ASMI 50 CHB + 
423 45 M S CP + 4 IR 80 II 190 270 AWMI 45 CCF - 
424 59 M M CP + 9 R 70 I 170 230 IWMI 54 - - 
425 63 M M BR + 8 IR 110 II 210 328 AWMI 40 CCF CHB + 
426 53 F S CP + 2 R 90 I 66 78 AWMI 50 - - 
427 67 F S BR + 3 IR 99 II 186 270 AWMI 44 CCF - 
428 44 M M CP + 8 R 80 I 99 140 ASMI 56 - - 
429 68 M M CP + 7 IR 90 II 216 320 AWMI 44 CCF - 
430 68 F S BR + 3 IR 90 II 230 290 AWMI 35 CCF - 
431 49 M M CP + 3 R 86 I 136 210 ASMI 50 - - 
432 66 F S CP + 4 R 90 I 160 236 IWMI 56 - - 
433 55 F S CP + 8 R 102 II 240 388 ASMI 48 CCF - 
434 65 M M CP + 3 R 80 I 168 220 ASMI 52 - - 
435 50 M S CP + 6 R 86 II 210 260 ALMI 50 CCF - 
436 34 M M CP + 1 R 72 I 140 240 ASMI 54 - - 
437 54 M S CP + 3 R 70 I 130 160 AWMI 50 - - 
438 40 M S CP + 4 R 92 II 180 234 AWMI 40 CCF - 
439 65 F S BR + 9 IR 66 II 126 190 ASMI 48 - - 
440 54 M S CP + 6 IR 86 I 177 280 ASMI 50 CCF - 
441 47 M M  CP + 4 IR 80 I 280 354 ASMI 56 - - 
442 40 M M CP + 7 IR 88 I 130 270 IWMI 56 - - 
443 40 M M CP + 8 IR 90 II 190 270 AWMI 42 CCF - 
444 54 M M CP + 1 IR 94 I 160 171 AWMI 46 CCF - 
445 61 F S BR + 4 IR 80 II 230 216 AWMI 35 CCF - 
446 57 M M CP + 8 R 89 I 93 196 ASMI 50 - - 
447 72 F S CP + 3 IR 98 II 260 290 ALMI 54 - - 
448 79 M M CP   + 8 R 100 I 130 218 ALMI 54 - - 
449 63 M S BR + 7 R 88 IV     ALMI   CCF VF + 
450 75 F S CP + 4 IR 60 I 130 210 AWMI 50 CHB - 
451 70 F S CP + 8 IR 88 I 170 201 AWMI 50 CHB - 
452 55 M M CP + 2 R 50 I 190 230 IWMI 58 - - 
453 53 M M CP + 2 R 84 I 130 160 AWMI 50 - - 
454 51 M M CP + 3 R 78 I 180 232 ASMI 50 - - 
455 64 M M CP + 9 IR 80 I 200 195 ASMI 56 - - 
456 72 M M CP + 1 IR 88 I 200 280 ASMI 56 - - 
457 63 M M CP + 7 IR 82 I 280 394 IWMI 56 - - 
  
458 39 M M BR + 4 R 78 II 180 240 IWMI 50 CCF CHB + 
459 74 M M CP + 4 R 84 II 118 136 ASMI 50 CCF - 
460 62 M M CP + 3 IR 86 I 310 358 ASMI 56 - - 
461 52 M M  BR + 3 IR 78 I 266 320 IWMI 56 - - 
462 58 F M CP + 4 R 82 I 128 240 IWMI 58 - - 
463 47 M M CP + 1 IR 86 I 189 225 AWMI 50 - - 
464 55 F S CP + 13 R 88 II 200 288 AWMI 48 CCF - 
465 56 M  M CP + 9 R 86 II 140 226 ASMI 57 CCF - 
466 44 M M CP + 3 IR 100 II 200 310 AWMI 40 CCF - 
467 70 M M CP + 3 IR 78 I 150 210 AWMI 54 - - 
468 70 M S CP + 4 R 90 I 170 326 AWMI 54 - - 
469 41 F S CP + 3 IR 99 I 126 400 ASMI 54 - - 
470 71 F S BR + 12 IR 74 II 210 316 AWMI 48 CCF VT - 
471 47 M M CP + 7 R 110 II 190 270 AWMI 50 CCF - 
472 51 M M CP + 3 IR 52 I 200 390 ASMI 60 - - 
473 35 F S CP + 3 IR 80 I 219 300 ASMI 56 - - 
474 65 M M CP + 4 R 88 I 130 170 ASMI 60 - - 
475 49 F S CP + 1 R 90 I 88 168 ALMI 60 - - 
476 48 M M CP + 7 IR 80 I 260 384 ASMI 60 - - 
477 55 M M BR + 9 R 100 III 96 118 AWMI 45 CCF - 
478 65 M M BR + 4 R 110 IV     AWMI   CCF,VF + 
479 37 M S CP + 3 IR 80 I 168 204 ASMI 50 - - 
480 52 M M BR + 8 R 90 II 140 210 AWMI 44 CCF - 
481 40 M S BR + 4 IR 96 IV     AWMI   CCF + 
482 34 M S CP + 3 R 90 I 288 348 ASMI 50 CHB + 
483 45 M S CP + 4 IR 80 II 190 270 AWMI 45 CCF - 
484 59 M M CP + 9 R 70 I 170 230 IWMI 54 - - 
485 63 M M BR + 8 IR 110 II 210 328 AWMI 40 CCF CHB + 
486 53 F S CP + 2 R 90 I 66 78 AWMI 50 - - 
487 67 F S BR + 3 IR 99 II 186 270 AWMI 44 CCF - 
488 44 M M CP + 8 R 80 I 99 140 ASMI 56 - - 
489 68 M M CP + 7 IR 90 II 216 320 AWMI 44 CCF - 
490 68 F S BR + 3 IR 90 IV     AWMI   CCF + 
491 49 M M CP + 3 R 86 I 136 210 ASMI 50 - - 
492 66 F S CP + 4 R 90 I 160 236 IWMI 56 - - 
493 55 F S CP + 8 R 102 II 240 388 ASMI 48 CCF - 
494 65 M M CP + 3 R 80 I 168 220 ASMI 52 - - 
495 50 M S CP + 6 R 86 II 210 260 ALMI 50 CCF - 
496 34 M M CP + 1 R 72 I 140 240 ASMI 54 - - 
497 54 M S CP + 3 R 70 I 130 160 AWMI 50 - - 
498 40 M S CP + 4 R 92 II 180 234 AWMI 40 CCF - 
499 65 F S BR + 9 IR 66 II 126 190 ASMI 48 - - 
500 54 M S CP + 6 IR 86 I 177 280 ASMI 50 CCF - 
501 46 M S CP + 3 IR 98 IV     AWMI   CCF + 
502 58 F S CP + 7 IR 92 I     IWMI   VF + 
503 65 F M CP + 8 R 80 I 186 320 ASMI 56 - - 
504 58 F M CP + 8 R 90 II 130 188 ASMI 54 CCF - 
505 63 M M CP + 4 IR 82 I 280 394 IWMI 56 - - 
506 39 M M CP + 3 R 80 II 180 240 IWMI 50 CHB - 
507 74 M M CP + 4 R 84 II 118 136 ASMI 50 - - 
508 52 M M BR + 3 IR 86 I 266 320 IWMI 56 - - 
509 58 F M CP + 4 R 82 I 128 240 IWMI 58 - - 
510 54 M M CP + 4 IR 86 I 189 225 AWMI 50 - - 
511 47 M M CP + 7 R 110 IV     AWMI   CCF + 
512 56 M M CP + 3 IR 98 I 136 200 IWMI 54 - - 
513 71 F S BR + 9 IR 74 IV     AWMI   CCF VT + 
514 41 M M CP + 2 IR 99 I 126 400 ASMI 54 - - 
515 58 M S CP + 1 R 90 I 170 326 AWMI 54 - - 
516 70 M M CP + 1 IR 78 I 150 210 AWMI 54 - - 
517 44 M M CP + 2 IR 100 II     AWMI   CCF + 
518 56 M M CP + 8 R 86 II 140 226 ASMI 57 - - 
519 62 M M CP + 3 IR 88 I 310 358 ASMI 56 - - 
 
